Hybio Pharmaceutical Co., Ltd.
300199
Hisse Senetlerindeki Sıralama
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Hisse Fiyatı
$3.69
Piyasa Değeri
$3.11B
Değişim (1 gün)
-7.75%
Değişim (1 yıl)
21.56%
Ülke
CN
Ticaret Hybio Pharmaceutical Co., Ltd. (300199)
Kategori
Healthcare
Hybio Pharmaceutical Co., Ltd. (300199) için gelir
Jun 2026 itibarıyla gelir TTM: $165.50M
Hybio Pharmaceutical Co., Ltd. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $165.50M'dir. 2024 yılında şirketin geliri $80.86M önceki yıla göre artış 2023 yılındaki $60.94M gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Hybio Pharmaceutical Co., Ltd. için 2007 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
| Yıl | Gelir | Değiştir |
|---|---|---|
| 2026 (TTM) | $165.50M | 19.82% |
| 2025 | $138.12M | 70.82% |
| 2024 | $80.86M | 32.68% |
| 2023 | $60.94M | -40.32% |
| 2022 | $102.11M | -11.82% |
| 2021 | $115.79M | 4.81% |
| 2020 | $110.48M | 25.25% |
| 2019 | $88.20M | -52.02% |
| 2018 | $183.82M | -4.03% |
| 2017 | $191.55M | 55.53% |
| 2016 | $123.15M | 4.10% |
| 2015 | $118.31M | 74.71% |
| 2014 | $67.72M | 36.28% |
| 2013 | $49.69M | 38.99% |
| 2012 | $35.75M | 38.27% |
| 2011 | $25.86M | 39.97% |
| 2010 | $18.47M | 36.03% |
| 2009 | $13.58M | 19.78% |
| 2008 | $11.34M | 47.29% |
| 2007 | $7.70M | 0.00% |
Benzer şirketler veya rakiplerin geliri
| Şirket | Gelir | Gelir Farkı | Ülke |
|---|---|---|---|
| $23.54B | 14,121.00% |
DE
|
|
| $23.73B | 14,241.61% |
DE
|
|
| $29.24B | 17,567.76% |
JP
|
|
| $5.85B | 3,434.05% |
CH
|
|
| $6.61B | 3,895.03% |
IN
|
